IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

Inclusion criteria

• Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
• Age ≥18 years old;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Expected survival time of ≥ 3 months;

Exclusion criteria

• CNS dysfunction with clinical significance. For example, seizures, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS.
• Any form of primary and acquired immunodeficiency (such as severe combined immunodeficiency). Known human immunodeficiency virus (HIV) positive subjects
• Have experienced myocardial infarction or unstable angina within the 6 months prior to screening
• Pleural effusion requiring drainage for symptom management within 28 days prior to screening